Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna has made significant progress with its Coronavirus vaccine candidate - mRNA-1273 - in recent weeks, as it gained FDA approval to begin phase 2 clinical trials while noting that it was finalizing the protocol for a phase 3 study, which is expected to begin early summer.

Why Moderna Is Clearly Pulling Ahead In The COVID Vaccine Race

Futures leaped in response at the possibility of a vaccine that could treat the virus.

Moderna Reveals ‘Positive’ Data In Coronavirus Vaccine Trial, Markets Spike

Shares of Lonza Group LONN, +2.80% climbed 2.9% in Swiss trade after Moderna MRNA, +3.29% reported positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus.

Lonza Group shares climb on positive Moderna vaccine trial

Shares of Moderna Inc. MRNA, +3.29% jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine.

Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidate

U.S. stock-index futures added to gains Monday morning, with the market for risk assets gathering additional momentum from a report of success in a vaccine for the COVID=19 pandemic.

Dow futures surge 550 points, adding to Monday gains as Moderna says it sees some success with coronavirus vaccine

Moderna’s closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants.

Moderna reports 'positive' data on early-stage coronavirus vaccine trial

Novavax

The biotechnology companies creating COVID-19 vaccines should give hope to patients and investors. Moderna and Novavax are no exception.

Moderna and Novavax are Making Strides in Advancing Novel Coronavirus Vaccine Research

Inovio Pharmaceuticals

The University of Oxford, which is partnering with large-cap pharma AstraZeneca plc (NYSE: AZN) to develop a vaccine for SARS-CoV-2, could lead the pack in advancing its vaccine candidate to the next stage.

Results From Oxford University's Human Trial Of Coronavirus Vaccine Could Arrive In June; Where Inovio, Moderna Stand

CRISPR Therapeutics

TG Therapeutics

By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.

The 3 Best Biotech Stocks to Own in 2020

A venture capitalist and former Gates Foundation investor, who years ago backed Covid-19 vaccine contender Moderna Therapeutics, weighs in on how to think about investing during the coronavirus pandemic.

An early backer of Moderna Therapeutics on the core investing lesson behind a big coronavirus bet

B&G Foods

Bristol-Myers

Clorox

Fortinet

ServiceNow

NVIDIA

At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.

Rebalance Your Portfolio to Counter Dilemma Over Recovery

Will Moderna become the winner in the race to find the vaccine for COVID-19?

Just How Promising Is Moderna's COVID-19 Vaccine?

Moderna Inc. (NASDAQ: MRNA) Chief Executive Officer Stephane Bancel on Tuesday told CNBC he is hoping for approval of multiple vaccines against the novel coronavirus (COVID-19).

Moderna CEO Says Company's Vaccine Alone Can't Meet Global Supply

The coronavirus vaccine trial that started out in Seattle is progressing well enough to get onto Food and Drug Administration’s fast track for development, with planning well underway for the next two phases of testing.

After positive results in Seattle, COVID-19 vaccine will face key trials this summer, Moderna CEO says

Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand.

Moderna CEO says no single drugmaker can produce enough coronavirus vaccine doses for the planet

MRNA stock jumped on the news its mRNA-1273 vaccine will start phase 2 trials any day, but now many question whether the hype is justified.
The post Can Moderna Stock Keep Its Place At the Front of the Pack?

Can Moderna Stock Keep Its Place At the Front of the Pack?

Trials on several hundred participants will begin in the coming weeks.

FDA ‘Fast Tracks’ First Coronavirus Vaccine From Moderna

Shares of Moderna Inc. MRNA, +12.91% gained 1.9% after the biotechnology company said it had received a fast-track designation from the Food and Drug Administration for its COVID-19 vaccine candidate.

Moderna's COVID-19 vaccine candidate gets a fast-track designation

Moderna Inc (NASDAQ: MRNA), which is developing an mRNA vaccine codenamed mRNA-1273 for the coronavirus, announced an incremental update concerning its vaccine program Tuesday, sending its shares further into record territory.

Moderna Stock Pushes To New Record On Fast Track Designation For Coronavirus Vaccine

Moderna on Tuesday its experimental coronavirus vaccine had gained the U.S. Food and Drug Administration's "fast track" designation.

Moderna's experimental coronavirus vaccine gets FDA's 'fast track' status

Being one of the leaders in the race to develop a vaccine for COVID-19 has its perks.

Why Moderna Is Rising (Again) Today

Moderna (NASDAQ: MRNA) is trading higher on Monday. Reuters reports Moderna has sped up plans for its COVID-19 vaccine and plans late stage human trials in early summer.

Why Moderna's Stock Is Trading Higher Today

What Happens Next To Moderna Stock After That Big Rally

Chegg

QuidelOrtho Corp

Wayfair

Market's worst is behind us as negative estimates are already factored in valuations.

News for Moderna Stock (MRNA)